Review



human phospho kinase array kit ary003  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    R&D Systems human phospho kinase array kit ary003
    Human Phospho Kinase Array Kit Ary003, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 823 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ary003+proteome+profiler/Proteome+Profiler+Human+Phospho-Kinase+Array+Kit/us12397037-1185-3-11
    Average 96 stars, based on 823 article reviews
    human phospho kinase array kit ary003 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Lysis:

    Article Title: Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases.
    Article Snippet: Many compounds structurally similar to chromones have been developed to enhance the sensitizing effect of cancer cells to chemotherapeutic agents.. Most of these compounds have been shown to promote this sensitization by targeting the repair pathways.. One such compound is LTUR6, which enhances the sensitization of doxorubicin to colon cancer cells HT29, by inhibiting the phosphorylation of the double stranded break (DSB) repair enzyme AKT.

    Protein Concentration:

    Article Title: Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases.
    Article Snippet: Many compounds structurally similar to chromones have been developed to enhance the sensitizing effect of cancer cells to chemotherapeutic agents.. Most of these compounds have been shown to promote this sensitization by targeting the repair pathways.. One such compound is LTUR6, which enhances the sensitization of doxorubicin to colon cancer cells HT29, by inhibiting the phosphorylation of the double stranded break (DSB) repair enzyme AKT.

    DC Protein Assay:

    Article Title: Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases.
    Article Snippet: Many compounds structurally similar to chromones have been developed to enhance the sensitizing effect of cancer cells to chemotherapeutic agents.. Most of these compounds have been shown to promote this sensitization by targeting the repair pathways.. One such compound is LTUR6, which enhances the sensitization of doxorubicin to colon cancer cells HT29, by inhibiting the phosphorylation of the double stranded break (DSB) repair enzyme AKT.



    Similar Products

    human phospho kinase array kit ary003  (R&D Systems)
    96
    R&D Systems human phospho kinase array kit ary003
    Human Phospho Kinase Array Kit Ary003, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ary003+proteome+profiler/Proteome+Profiler+Human+Phospho-Kinase+Array+Kit/us12397037-1185-3-11
    Average 96 stars, based on 1 article reviews
    human phospho kinase array kit ary003 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    proteome profiler human phospho kinase array kit ary003  (R&D Systems)
    98
    R&D Systems proteome profiler human phospho kinase array kit ary003
    Proteome Profiler Human Phospho Kinase Array Kit Ary003, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ary003+proteome+profiler/Proteome+Profiler+Human+Phospho-Kinase+Array+Kit/pmc08363746-344-6-13
    Average 98 stars, based on 1 article reviews
    proteome profiler human phospho kinase array kit ary003 - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    ary003  (R&D Systems)
    98
    R&D Systems ary003
    (A) To identify downstream signalling pathways activated by HIP1 overexpression membrane A of the Human phospho-kinase array <t>(ARY003)</t> used to de-termine the relative levels of phosphorylated proteins of 46 specific kinases and substrates. Lysates were prepared from PNT1A-empty vector (EV) and PNT1A-HIP1 cell lines grown in full serum. The intensity of array spots in duplicate were analysed with ImageQUANT™ software. (B) Immunoblot of PNT1a-EV and PNT1a-HIP1 lysates for HIP1, p-STAT3(Y705) and actin. Relative levels of phosphorylation of STAT3 in PNT1a-HIP1 normalised to the control cell line after correction for equal protein loading control is displayed below blots. (C) Immunoblot of HIP1, p-STAT3(Y705) upon transient ectopic expression of GFP-HIP1 in the PNT1a-EV control for 48 hours. (D) Immunoblots of HIP1 and pSTAT3 in NIH3T3 cells transiently overexpressing HIP1. (E) Immunoblots of HIP1, p-STAT3(Y705), and p-FGFR following stable knockdown of HIP1 in PNT1a-HIP1 using shRNA compared to scrambled control. Fold changes indicated were normalised to actin. (F) WP1066 pre-treatment blocked STAT3 phosphorylation upon FGF2 stimulation in HIP1 overexpressing cells. PNT1A-HIP1 and PNT1A-EV were serum starved for 24 hours, pre-treated with DMSO or kinase inhibitors for one hour and stimulated with FGF2 (20ng/ml). Comparison of treatments with PI3K inhibitor (LY294002), Jak2 inhibitor (WP1066), MEK1/2 inhibitor (U0126), FGFR phosphorylation inhibitor (PD173074). (G) Drug treatment of PNT1A cells cultured in full serum conditions. PNT1A-EV and PNT1A-HIP1 cells cultured in full serum were treated with JAK2 kinase inhibitor (WP1066), MEK1/2 kinase inhibitor (U1026) and FGFR phosphorylation inhibitor (PD173074).
    Ary003, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ary003+proteome+profiler/Proteome+Profiler+Human+Phospho-Kinase+Array+Kit/bio_rxiv__2020__07__09__191734-37-12-10
    Average 98 stars, based on 1 article reviews
    ary003 - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    ary003 proteome profiler  (R&D Systems)
    96
    R&D Systems ary003 proteome profiler
    (A) To identify downstream signalling pathways activated by HIP1 overexpression membrane A of the Human phospho-kinase array <t>(ARY003)</t> used to de-termine the relative levels of phosphorylated proteins of 46 specific kinases and substrates. Lysates were prepared from PNT1A-empty vector (EV) and PNT1A-HIP1 cell lines grown in full serum. The intensity of array spots in duplicate were analysed with ImageQUANT™ software. (B) Immunoblot of PNT1a-EV and PNT1a-HIP1 lysates for HIP1, p-STAT3(Y705) and actin. Relative levels of phosphorylation of STAT3 in PNT1a-HIP1 normalised to the control cell line after correction for equal protein loading control is displayed below blots. (C) Immunoblot of HIP1, p-STAT3(Y705) upon transient ectopic expression of GFP-HIP1 in the PNT1a-EV control for 48 hours. (D) Immunoblots of HIP1 and pSTAT3 in NIH3T3 cells transiently overexpressing HIP1. (E) Immunoblots of HIP1, p-STAT3(Y705), and p-FGFR following stable knockdown of HIP1 in PNT1a-HIP1 using shRNA compared to scrambled control. Fold changes indicated were normalised to actin. (F) WP1066 pre-treatment blocked STAT3 phosphorylation upon FGF2 stimulation in HIP1 overexpressing cells. PNT1A-HIP1 and PNT1A-EV were serum starved for 24 hours, pre-treated with DMSO or kinase inhibitors for one hour and stimulated with FGF2 (20ng/ml). Comparison of treatments with PI3K inhibitor (LY294002), Jak2 inhibitor (WP1066), MEK1/2 inhibitor (U0126), FGFR phosphorylation inhibitor (PD173074). (G) Drug treatment of PNT1A cells cultured in full serum conditions. PNT1A-EV and PNT1A-HIP1 cells cultured in full serum were treated with JAK2 kinase inhibitor (WP1066), MEK1/2 kinase inhibitor (U1026) and FGFR phosphorylation inhibitor (PD173074).
    Ary003 Proteome Profiler, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ary003+proteome+profiler/Proteome+Profiler+Human+Phospho-Kinase+Array+Kit/pm30627877-48-8-11
    Average 96 stars, based on 1 article reviews
    ary003 proteome profiler - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    ary003 proteome profiler tm  (R&D Systems)
    96
    R&D Systems ary003 proteome profiler tm
    (A) To identify downstream signalling pathways activated by HIP1 overexpression membrane A of the Human phospho-kinase array <t>(ARY003)</t> used to de-termine the relative levels of phosphorylated proteins of 46 specific kinases and substrates. Lysates were prepared from PNT1A-empty vector (EV) and PNT1A-HIP1 cell lines grown in full serum. The intensity of array spots in duplicate were analysed with ImageQUANT™ software. (B) Immunoblot of PNT1a-EV and PNT1a-HIP1 lysates for HIP1, p-STAT3(Y705) and actin. Relative levels of phosphorylation of STAT3 in PNT1a-HIP1 normalised to the control cell line after correction for equal protein loading control is displayed below blots. (C) Immunoblot of HIP1, p-STAT3(Y705) upon transient ectopic expression of GFP-HIP1 in the PNT1a-EV control for 48 hours. (D) Immunoblots of HIP1 and pSTAT3 in NIH3T3 cells transiently overexpressing HIP1. (E) Immunoblots of HIP1, p-STAT3(Y705), and p-FGFR following stable knockdown of HIP1 in PNT1a-HIP1 using shRNA compared to scrambled control. Fold changes indicated were normalised to actin. (F) WP1066 pre-treatment blocked STAT3 phosphorylation upon FGF2 stimulation in HIP1 overexpressing cells. PNT1A-HIP1 and PNT1A-EV were serum starved for 24 hours, pre-treated with DMSO or kinase inhibitors for one hour and stimulated with FGF2 (20ng/ml). Comparison of treatments with PI3K inhibitor (LY294002), Jak2 inhibitor (WP1066), MEK1/2 inhibitor (U0126), FGFR phosphorylation inhibitor (PD173074). (G) Drug treatment of PNT1A cells cultured in full serum conditions. PNT1A-EV and PNT1A-HIP1 cells cultured in full serum were treated with JAK2 kinase inhibitor (WP1066), MEK1/2 kinase inhibitor (U1026) and FGFR phosphorylation inhibitor (PD173074).
    Ary003 Proteome Profiler Tm, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ary003+proteome+profiler/Proteome+Profiler+Human+Phospho-Kinase+Array+Kit/pmc06791869-97-17-22
    Average 96 stars, based on 1 article reviews
    ary003 proteome profiler tm - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    assays proteome profiler human phospho kinase array r d systems ary003 duolink proximity ligation assay pla  (R&D Systems)
    98
    R&D Systems assays proteome profiler human phospho kinase array r d systems ary003 duolink proximity ligation assay pla
    (A) To identify downstream signalling pathways activated by HIP1 overexpression membrane A of the Human phospho-kinase array <t>(ARY003)</t> used to de-termine the relative levels of phosphorylated proteins of 46 specific kinases and substrates. Lysates were prepared from PNT1A-empty vector (EV) and PNT1A-HIP1 cell lines grown in full serum. The intensity of array spots in duplicate were analysed with ImageQUANT™ software. (B) Immunoblot of PNT1a-EV and PNT1a-HIP1 lysates for HIP1, p-STAT3(Y705) and actin. Relative levels of phosphorylation of STAT3 in PNT1a-HIP1 normalised to the control cell line after correction for equal protein loading control is displayed below blots. (C) Immunoblot of HIP1, p-STAT3(Y705) upon transient ectopic expression of GFP-HIP1 in the PNT1a-EV control for 48 hours. (D) Immunoblots of HIP1 and pSTAT3 in NIH3T3 cells transiently overexpressing HIP1. (E) Immunoblots of HIP1, p-STAT3(Y705), and p-FGFR following stable knockdown of HIP1 in PNT1a-HIP1 using shRNA compared to scrambled control. Fold changes indicated were normalised to actin. (F) WP1066 pre-treatment blocked STAT3 phosphorylation upon FGF2 stimulation in HIP1 overexpressing cells. PNT1A-HIP1 and PNT1A-EV were serum starved for 24 hours, pre-treated with DMSO or kinase inhibitors for one hour and stimulated with FGF2 (20ng/ml). Comparison of treatments with PI3K inhibitor (LY294002), Jak2 inhibitor (WP1066), MEK1/2 inhibitor (U0126), FGFR phosphorylation inhibitor (PD173074). (G) Drug treatment of PNT1A cells cultured in full serum conditions. PNT1A-EV and PNT1A-HIP1 cells cultured in full serum were treated with JAK2 kinase inhibitor (WP1066), MEK1/2 kinase inhibitor (U1026) and FGFR phosphorylation inhibitor (PD173074).
    Assays Proteome Profiler Human Phospho Kinase Array R D Systems Ary003 Duolink Proximity Ligation Assay Pla, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ary003+proteome+profiler/Proteome+Profiler+Human+Phospho-Kinase+Array+Kit/pmc06452716__pnas__1817415116__sapp-33-199-205
    Average 98 stars, based on 1 article reviews
    assays proteome profiler human phospho kinase array r d systems ary003 duolink proximity ligation assay pla - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) To identify downstream signalling pathways activated by HIP1 overexpression membrane A of the Human phospho-kinase array (ARY003) used to de-termine the relative levels of phosphorylated proteins of 46 specific kinases and substrates. Lysates were prepared from PNT1A-empty vector (EV) and PNT1A-HIP1 cell lines grown in full serum. The intensity of array spots in duplicate were analysed with ImageQUANT™ software. (B) Immunoblot of PNT1a-EV and PNT1a-HIP1 lysates for HIP1, p-STAT3(Y705) and actin. Relative levels of phosphorylation of STAT3 in PNT1a-HIP1 normalised to the control cell line after correction for equal protein loading control is displayed below blots. (C) Immunoblot of HIP1, p-STAT3(Y705) upon transient ectopic expression of GFP-HIP1 in the PNT1a-EV control for 48 hours. (D) Immunoblots of HIP1 and pSTAT3 in NIH3T3 cells transiently overexpressing HIP1. (E) Immunoblots of HIP1, p-STAT3(Y705), and p-FGFR following stable knockdown of HIP1 in PNT1a-HIP1 using shRNA compared to scrambled control. Fold changes indicated were normalised to actin. (F) WP1066 pre-treatment blocked STAT3 phosphorylation upon FGF2 stimulation in HIP1 overexpressing cells. PNT1A-HIP1 and PNT1A-EV were serum starved for 24 hours, pre-treated with DMSO or kinase inhibitors for one hour and stimulated with FGF2 (20ng/ml). Comparison of treatments with PI3K inhibitor (LY294002), Jak2 inhibitor (WP1066), MEK1/2 inhibitor (U0126), FGFR phosphorylation inhibitor (PD173074). (G) Drug treatment of PNT1A cells cultured in full serum conditions. PNT1A-EV and PNT1A-HIP1 cells cultured in full serum were treated with JAK2 kinase inhibitor (WP1066), MEK1/2 kinase inhibitor (U1026) and FGFR phosphorylation inhibitor (PD173074).

    Journal: bioRxiv

    Article Title: HIP1 mediates oncogenic transformation and cancer progression through STAT3 signalling

    doi: 10.1101/2020.07.09.191734

    Figure Lengend Snippet: (A) To identify downstream signalling pathways activated by HIP1 overexpression membrane A of the Human phospho-kinase array (ARY003) used to de-termine the relative levels of phosphorylated proteins of 46 specific kinases and substrates. Lysates were prepared from PNT1A-empty vector (EV) and PNT1A-HIP1 cell lines grown in full serum. The intensity of array spots in duplicate were analysed with ImageQUANT™ software. (B) Immunoblot of PNT1a-EV and PNT1a-HIP1 lysates for HIP1, p-STAT3(Y705) and actin. Relative levels of phosphorylation of STAT3 in PNT1a-HIP1 normalised to the control cell line after correction for equal protein loading control is displayed below blots. (C) Immunoblot of HIP1, p-STAT3(Y705) upon transient ectopic expression of GFP-HIP1 in the PNT1a-EV control for 48 hours. (D) Immunoblots of HIP1 and pSTAT3 in NIH3T3 cells transiently overexpressing HIP1. (E) Immunoblots of HIP1, p-STAT3(Y705), and p-FGFR following stable knockdown of HIP1 in PNT1a-HIP1 using shRNA compared to scrambled control. Fold changes indicated were normalised to actin. (F) WP1066 pre-treatment blocked STAT3 phosphorylation upon FGF2 stimulation in HIP1 overexpressing cells. PNT1A-HIP1 and PNT1A-EV were serum starved for 24 hours, pre-treated with DMSO or kinase inhibitors for one hour and stimulated with FGF2 (20ng/ml). Comparison of treatments with PI3K inhibitor (LY294002), Jak2 inhibitor (WP1066), MEK1/2 inhibitor (U0126), FGFR phosphorylation inhibitor (PD173074). (G) Drug treatment of PNT1A cells cultured in full serum conditions. PNT1A-EV and PNT1A-HIP1 cells cultured in full serum were treated with JAK2 kinase inhibitor (WP1066), MEK1/2 kinase inhibitor (U1026) and FGFR phosphorylation inhibitor (PD173074).

    Article Snippet: The Prosphoproteome array was used according to the manufacturer’s instructions (R&D systems, # ARY003) with 400μg of protein used per membrane.

    Techniques: Over Expression, Membrane, Plasmid Preparation, Software, Western Blot, Expressing, shRNA, Comparison, Cell Culture